Glaukos shares hit record $184.45 amid strong market demand
Medical device maker Glaukos surged to an all-time high as investors bet on sustained demand for its glaucoma treatments. Volume outpaced its 30-day average.
Glaukos Corp’s stock reached an unprecedented $184.45 on Tuesday, marking a new all-time high for the medical device manufacturer as trading volume surpassed its 30-day average.
The milestone comes amid growing investor confidence in Glaukos’ glaucoma treatment portfolio, which includes its flagship iStent inject device. The company has reported consistent revenue growth in recent quarters, driven by increased adoption of its minimally invasive glaucoma surgery (MIGS) solutions.
Analysts attributed the rally to strong procedural demand and favorable reimbursement policies in key markets. The stock’s surge also reflects broader investor enthusiasm for medical technology stocks with clear clinical and commercial advantages.
Glaukos has not provided an official comment on the price movement. The company’s next earnings report is scheduled for late October, which may offer further insight into its operational performance and guidance.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →